首页> 外文期刊>Clinical Psychopharmacology and Neuroscience >Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision
【24h】

Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision

机译:韩国双相情感障碍药物治疗算法项目2018(KMAP-BP 2018):第四次修订

获取原文
           

摘要

Objective The Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) was first published in 2002 through an expert consensus of opinion, and updated in 2006, 2010, and 2014. This study constitutes the fourth revision of the KMAP-BP. Methods A 50-item questionnaire was used to obtain the consensus of experts regarding pharmacological treatment strategies for various phases of adult bipolar disorder and six items for pediatric bipolar disorder. The review committee included 84 Korean psychiatrists and 43 child and adolescent psychiatry experts. Results The preferred first-step strategies for acute mania were the combination of a mood stabilizer (MS) and an atypical antipsychotic (AAP), MS monotherapy, and AAP monotherapy. A combination of a MS and an AAP, and AAP monotherapy were preferred for psychotic mania. The first-step strategies for mild to moderate bipolar depression were monotherapy with MS, AAP, or lamotrigine (LMT), and the combination of a MS and an AAP or LMT, or a combination of an AAP and LMT. The combination of two among a MS, AAP, and LMT were preferred for non-psychotic severe depression. A combination of a MS and an AAP or the combination of an AAP with an antidepressant or LMT were the first-line options for psychotic severe depression. Conclusion The recommendations of the KMAP-BP 2018 have changed from the previous version by reflecting recent developments in pharmacotherapy for bipolar disorder. KMAP-BP 2018 provides clinicians with a wealth of information regarding appropriate strategies for treating patients with bipolar disorder.
机译:目的韩国双相情感障碍用药算法项目(KMAP-BP)于2002年通过专家意见共识首次发布,并于2006、2010和2014年进行了更新。该研究构成了KMAP-BP的第四次修订。方法采用50项问卷调查,就成年双相情感障碍各个阶段和六项小儿双相情感障碍的药物治疗策略达成专家共识。审查委员会由84名韩国精神科医生和43名儿童和青少年精神病专家组成。结果对于急性躁狂症,首选的首选策略是将情绪稳定剂(MS)和非典型抗精神病药(AAP),MS单一疗法和AAP单一疗法相结合。 MS和AAP的组合,以及AAP单一疗法对于精神病性躁狂症更可取。轻度至中度双相抑郁症的第一步策略是单药联合MS,AAP或拉莫三嗪(LMT),以及MS与AAP或LMT的组合,或AAP与LMT的组合。对于非精神病性重度抑郁症,首选将MS,AAP和LMT两者结合使用。 MS和AAP的组合或AAP与抗抑郁药或LMT的组合是精神病性严重抑郁的一线选择。结论KMAP-BP 2018的建议与以前的版本有所不同,因为它反映了躁郁症药物治疗的最新进展。 KMAP-BP 2018为临床医生提供了大量有关治疗躁郁症的适当策略的信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号